The UK market has recently faced challenges, with the FTSE 100 closing lower due to weak trade data from China and broader global economic concerns. In this environment, identifying high-growth tech stocks becomes crucial as investors seek opportunities that can thrive despite broader market volatility.
Top 10 High Growth Tech Companies In The United Kingdom
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| STV Group | 13.15% | 46.78% | ★★★★★☆ |
| Gaming Realms | 11.57% | 22.07% | ★★★★★☆ |
| YouGov | 14.29% | 29.79% | ★★★★★☆ |
| Altitude Group | 23.46% | 27.56% | ★★★★★☆ |
| Facilities by ADF | 52.00% | 144.70% | ★★★★★☆ |
| Redcentric | 4.89% | 63.79% | ★★★★★☆ |
| Windar Photonics | 63.60% | 126.92% | ★★★★★☆ |
| Beeks Financial Cloud Group | 24.63% | 57.95% | ★★★★★☆ |
| Oxford Biomedica | 20.98% | 106.13% | ★★★★★☆ |
| Vinanz | 113.60% | 125.86% | ★★★★★☆ |
Click here to see the full list of 47 stocks from our UK High Growth Tech and AI Stocks screener.
Let’s review some notable picks from our screened stocks.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Genus plc is an animal genetics company with operations across North America, Latin America, the United Kingdom, Europe, the Middle East, Russia, Africa, and Asia and has a market cap of £1.32 billion.
Operations: Genus plc generates revenue primarily through its Genus ABS and Genus PIC segments, contributing £314.9 million and £352.5 million respectively. The company operates globally, including regions such as North America, Latin America, the UK, Europe, the Middle East, Russia, Africa, and Asia.
Despite a challenging year with earnings declining by 76.3%, Genus plc maintains a robust forecast with expected earnings growth at an impressive 39.4% annually, outpacing the UK market prediction of 14.3%. This resilience is underscored by their commitment to R&D, crucial for staying competitive in biotech innovation. However, revenue growth projections remain modest at 4.1% annually, slightly above the UK market’s 3.8%. The company also upheld its dividend payout at 21.7 pence per share, demonstrating confidence in its financial stability and commitment to shareholder returns amidst fluctuating profits and a significant one-off loss of £47.4 million last fiscal year.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: NCC Group plc operates in the cyber and software resilience sectors across the United Kingdom, Asia-Pacific, North America, and Europe with a market cap of £542.72 million.
Operations: NCC Group plc’s primary revenue streams come from Cyber Security (£258.50 million) and Escode (£65.90 million). The company operates in various regions, including the United Kingdom, Asia-Pacific, North America, and Europe.
NCC Group, recently added to the FTSE 250 and 350 indices, shows a promising trajectory with forecasted revenue growth of 4.5% annually, outpacing the UK market’s 3.8%. Despite current unprofitability, earnings are expected to surge by an impressive 87.4% per year as the company moves towards profitability within three years. This growth is supported by strategic investments in R&D which have positioned NCC for future technological advancements and market competitiveness.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide with a market cap of £401.88 million.
Operations: The company generates revenue primarily from its platform segment, totaling £97.24 million.
Oxford Biomedica’s trajectory in the biotech sector is underscored by its aggressive R&D investment, aligning with a projected revenue growth of 21% annually through 2026. This growth is significantly above the UK market average of 3.8%, showcasing its potential to outpace industry norms. Furthermore, with earnings expected to surge by an impressive 106% per year, the firm is on a path to profitability within three years—a testament to its strategic focus and operational adjustments following recent leadership enhancements, including the appointment of Lucinda Crabtree as CFO. These factors collectively highlight Oxford Biomedica’s robust approach toward capturing market share and enhancing shareholder value in a competitive landscape.
Taking Advantage
Want To Explore Some Alternatives?
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
